Belite Bio, INC (BLTE) — 20-F Filings

All 20-F filings from Belite Bio, INC. Browse 3 Foreign Annual Report reports with AI-powered summaries and risk analysis.

20-F Filings (3)

Belite Bio's Future Hinges on Tinlarebant as Cash Outflows Continue — Mar 31, 2026 Risk: high
Belite Bio, Inc. (BLTE) reported no revenue for the fiscal year ended December 31, 2025, consistent with its pre-commercial stage as a clinical-stage biopharmac
Belite Bio Files 2024 Annual Report — Mar 17, 2025 Risk: medium
Belite Bio, Inc. filed its 20-F annual report for the fiscal year ending December 31, 2024. The company, located at 12750 High Bluff Drive, Suite 475, San Diego
Belite Bio, Inc. Files 20-F Annual Report for Fiscal Year Ended December 31, 2023 — Mar 12, 2024 Risk: medium
BELITE BIO, INC (BLTE) filed a Foreign Annual Report (20-F) with the SEC on March 12, 2024. Belite Bio, Inc. filed its 20-F annual report for the fiscal year en

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX